Abstract
Transcranial current stimulation (tCS) techniques have been shown to induce cortical plasticity. As an important relay in the motor system, the cerebellum is an interesting target for plasticity induction using tCS, aiming to modulate its excitability and connectivity. However, until now it remains unclear, which is the most effective tCS method for inducing plasticity in the cerebellum. Thus, in this study, the effects of anodal transcranial direct current stimulation (tDCS), 50 Hz transcranial alternating current stimulation (50 Hz tACS), and high frequency transcranial random noise stimulation (tRNS) were compared with sham stimulation in 20 healthy subjects in a within-subject design. tCS was applied targeting the cerebellar lobe VIIIA using neuronavigation. We measured corticospinal excitability, short-interval intracortical inhibition (SICI), short-latency afferent inhibition (SAI), and cerebellar brain inhibition (CBI) and performed a sensor-based movement analysis at baseline and three times after the intervention (post1 = 15 min; post2 = 55 min; post3 = 95 min). Corticospinal excitability increased following cerebellar tACS and tRNS compared to sham stimulation. This effect was most pronounced directly after stimulation but lasted for at least 55 min after tACS. Cortico-cortical and cerebello-cortical conditioning protocols, as well as sensor-based movement analyses, did not change. Our findings suggest that cerebellar 50 Hz tACS is the most effective protocol to change corticospinal excitability.
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | 987472 |
| Seitenumfang | 12 |
| Fachzeitschrift | Frontiers in Neuroscience |
| Jahrgang | 16 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 15 Sept. 2022 |
Bibliographische Notiz
Funding Information:RH was supported by the Clinician Scientist Program of the Section of Medicine of the University of Lübeck (CS08-2020). MP was supported by the German Research Foundation (DFG) via the Clinician Scientist Program of the Clinical Scientist School Lübeck (CSSL) (DFG-GEPRIS 413535489). ER was supported by the German Research Foundation (DFG, No #430054590 project TRAIN). AM received commercial research support from Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion; honoraria for lectures from Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion, GlaxoSmithKline, Desitin, Teva, Takeda. AM was also supported from the Foundations Possehl-Stiftung (Lübeck, Germany), Margot und Jürgen Wessel Stiftung (Lübeck, Germany), Tourette Syndrome Association (Germany), Interessenverband Tourette Syndrom (Germany), CHDI and Damp-Stiftung (Kiel, Germany). AM further received academic research support from the German Research Foundation [DFG; projects 1692/3-1, 4-1, SFB 936, and FOR 2698 (project numbers: 396914663, 396577296, and 396474989)] and the European Reference Network—Rare Neurological Diseases (ERN—RND; Project ID No 739510). TMB received speaker and consultant fees from Pelzerhaken Children’s Centre, Allergan/Abbvie, Ipsen Pharma and Merz Pharmaceuticals. TMB has received research funding from the German Research Foundation (FG 2698 and SFB 936) and Ipsen Pharma and supported with exhibition ultrasound equipment on loan from Cannon and ESAOTE. AW has received funding from the Else Kröner-Fresenius foundation (EKFS, 2018_A55) and the German Research Foundation (DFG, WE5919/2-1).
Funding Information:
RH was supported by the Clinician Scientist Program of the Section of Medicine of the University of Lübeck (CS08-2020). MP was supported by the German Research Foundation (DFG) via the Clinician Scientist Program of the Clinical Scientist School Lübeck (CSSL) (DFG-GEPRIS 413535489). ER was supported by the German Research Foundation (DFG, No #430054590 project TRAIN). AM received commercial research support from Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion; honoraria for lectures from Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion, GlaxoSmithKline, Desitin, Teva, Takeda. AM was also supported from the Foundations Possehl-Stiftung (Lübeck, Germany), Margot und Jürgen Wessel Stiftung (Lübeck, Germany), Tourette Syndrome Association (Germany), Interessenverband Tourette Syndrom (Germany), CHDI and Damp-Stiftung (Kiel, Germany). AM further received academic research support from the German Research Foundation [DFG; projects 1692/3-1, 4-1, SFB 936, and FOR 2698 (project numbers: 396914663, 396577296, and 396474989)] and the European Reference Network—Rare Neurological Diseases (ERN—RND; Project ID No 739510). TMB received speaker and consultant fees from Pelzerhaken Children’s Centre, Allergan/Abbvie, Ipsen Pharma and Merz Pharmaceuticals. TMB has received research funding from the German Research Foundation (FG 2698 and SFB 936) and Ipsen Pharma and supported with exhibition ultrasound equipment on loan from Cannon and ESAOTE. AW has received funding from the Else Kröner-Fresenius foundation (EKFS, 2018_A55) and the German Research Foundation (DFG, WE5919/2-1).
Publisher Copyright:
Copyright © 2022 Herzog, Berger, Pauly, Xue, Rueckert, Münchau, Bäumer and Weissbach.